TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04431960

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: blackcurrant (BC) extract
Description: A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: blackcurrant (BC) extract
Description: A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: blackcurrant (BC) extract
Description: A calcium citrate caplet (Bayer AG, Germany) will be taken by all 3 groups to avoid bone deterioration related to calcium and vitamin D deficiency
Study: NCT05940558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-118 oral capsules
Description: MBF-118 oral capsules PPAR gamma receptor partial agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-118 oral capsules
Description: MBF-118 oral capsules PPAR gamma receptor partial agonist
Study: NCT05712603

Intervention type: DIAGNOSTIC_TEST
Intervention: FIB4-score
Description: A score which estimates the risk for advanced liver fibrosis, based on: age, ALT, AST and thrombocytes

Intervention type: DIAGNOSTIC_TEST
Intervention: Vibration controlled transient elastography
Description: VCTE measures the speed of a mechanically generated shear wave across the liver to derive a liver stiffness measurement (LSM), a marker of hepatic fibrosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Enhanced Liver Fibrosis test
Description: The ELF-test is a non-invasive blood test that measures three direct markers of liver fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1).
Study: NCT06648226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health swaps
Description: Participants will view health grade labels on all products in the online grocery store indicating their healthfulness as estimated by United Kingdom Ofcom Nutrient Profiling Model scores. The health score labels will mimic Nutri-Score labels, a labeling system used in some European countries, showing a color-coded grade of A (green) through F (red) on each product. Products with A and B labels will meet the United Kingdom's cutoff for products that can be marketed to children and C, D and F labels products are less healthy than this cutoff (based on tertiles of Ofcom scores within each food group). When participants attempt to add a less healthy product to their cart (e.g., C, D or F health label), the store will automatically suggest a healthier product from the same category (e.g., with a A or B health label).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environment swaps
Description: Participants will view climate grade labels on all products indicating their climate impact. The climate impact is calculated as the greenhouse gas emissions associated with producing the product in carbon dioxide equivalents (CO2-eq) per 100g (i.e., carbon footprint). Labels will be applied based on quintiles of carbon footprints in each food group. When participants attempt to add a high-climate-impact product to their cart (e.g., with a C, D, or F climate label), the store will automatically offer them swaps to more environmentally sustainable products (e.g., with a A or B climate label).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined health and environment swaps
Description: Participants will view both the health and climate grade labels on all products in the online grocery store. When participants attempt to select a product with a C, D, or F label on either dimension to their cart, the store will automatically offer them swaps to products that offer improvement over the original food on at least 1 dimension (health or environmental sustainability) and were at least as good or better on the other dimension, with the additional guardrail that the store never suggests products with a C, D or F label on either dimension.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants will not view any extra labels or be offered any swaps in the online grocery store.
Study: NCT06647862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM01
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT06650371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl infusion
Description: opioid based anesthesia analgesia will be offered by fentanyl in induction and maintenance according to Ideal Body Weight (IBW).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamedomedine and ketamine infusion
Description: Analgesia will be offered by syringe containing ketamine and Dexmedetomidine in induction and maintenance according to IBW.
Study: NCT06650488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Patients will change from aspirin to clopidogrel (without loading dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Patients will continue their existing aspirin.
Study: NCT06653595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programme to Support Breastfeeding
Description: The intervention consists of active support for breastfeeding by a lactation expert and IBCLC until the premature baby is 6 months old. The intervention includes: 1 face-to-face pre-discharge session, 8 home sessions up to 4 months and 3 telephone sessions up to 6 months.
Study: NCT06652945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Description: Uterine artery embolization under fluoroscopy
Study: NCT06175468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formosa 1-Breath Free (NRICM101)
Description: After screening, the treatment of this study is divided into two groups: The treatment group is Formosa 1-Breath Free (NRICM101) granule 5g/bag, 3 times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control drug
Description: After screening, the treatment of this study is divided into two groups: The placebo control group is the placebo (dummy) 5g/bag, 3 times a day.
Study: NCT06264011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salaat
Description: While Muslims perform mandatory salaat (prayer) 5 times daily, the Duha salaat is an optional daily prayer consisting of 4 cycles of standing, bowing, standing again, prostrating, kneeling, and prostrating again. Research has shown that salaat may influence physiological relaxation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: Participants will count while mimicking the movements of the Duhaa salaat. This is a no-prayer condition in which the recitation of Qur'an is omitted for the sake of comparison.
Study: NCT06244134

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided autologous blood injection
Description: guided

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: non guided autologous blood injection
Description: non guided
Study: NCT05749900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab+Nivolumab+Gemcitabine+Cisplatin
Description: Phase Ib Nivolumab 360mg IV q 3weeks Gemcitabine 1000mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks Level -1 Nivolumab 360mg IV q 3weeks Gemcitabine 800mg/m2 IV D1, D8 q 3weeks Cisplatin 25mg/m2 IV D1, D8 q 3weeks Trastuzumab 8mg/kg (C1) then 6mg/kg IV q 3weeks
Study: NCT06651073

Intervention type: OTHER
Intervention: Observational
Description: There is no intervention involved in the study. It is purely observational.
Study: NCT06538155

Intervention type: DEVICE
Intervention: Wearable device
Description: Wearable devices that are preferentially Food and Drug Administration (FDA) and/or Conformité Européenne (CE) marked

Intervention type: OTHER
Intervention: Cardiopulmonary resuscitation
Description: Cardiopulmonary resuscitation

Intervention type: OTHER
Intervention: CT scan, TEE exam, or chest X ray
Description: Chest CT scan, transesophageal echocardiogram (TEE) scans, or chest X ray

Intervention type: OTHER
Intervention: CT scan, TEE exam, or chest X ray
Description: Chest CT scan, transesophageal echocardiogram (TEE) scans, or chest X ray
Study: NCT06003283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV rituximab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: IV rituximab
Study: NCT06091150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular management of direct carotid-cavernous fistula
Description: Coiling and embolization of direct carotid-cavernous fistula
Study: NCT06493058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone positioning
Description: The babies in the study group were given the supine, right lateral and left lateral positions (12×1), which are used in nursing care practices in the clinic after extubation, in addition to the supine, right lateral and left lateral positions (12×1), the prone position was given twice a day for 2×2 hours twice a day within 48 hours after extubation, with the head on the midline of the neck and the head facing to the right or left side.
Study: NCT05594719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shorter-wavelength dominant light
Description: Shorter-wavelength dominant light

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shorter-wavelength dominant light
Description: Shorter-wavelength dominant light

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light similar to the solar spectrum proportion
Description: Light similar to the solar spectrum proportion with no specific wavelength dominant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Longer-wavelength dominant light
Description: Longer-wavelength dominant light
Study: NCT04668768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Glucarpidase injection to prevent toxicities due to high dose methotrexate treatment
Study: NCT06402058

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rejuran®
Description: Apply a maximum of 1.0 ml for each side of the Crow's Feet Lines using both the test device (DMSB01) and the control device (Rejuran®).
Study: NCT04909086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical Therapy
Description: Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), muscle stretching, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain
Description: Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of seated leg press and partial squat exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain
Description: Patients assigned to this group will receive a 40-min multimodal supervised physical therapy treatment comprised of warm-up (10-min cycling/walking), three sets of 10 repetitions of 60% of one-repetition maximum (1RM) of Quadriceps seated strengthening and Hamstring curl-up exercises, neuromuscular control exercises, and ten-minute transcutaneous electrical nerve stimulation (TENS). Manual mobilization techniques may be applied as necessary according to the findings of the physical examination. Treating physical therapists will prescribe exercises based on a predetermined list of exercises.
Study: NCT05220306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring of vital signs
Description: The MouthLab is a hand-held device. The user holds the unit in their left hand with the Mouthpiece between the teeth and lips and breathes normally into the device for 30 seconds.
Study: NCT04880096

Intervention type: OTHER
Intervention: eDOL
Description: e-health tool (mobile app for patients and web platform for caregivers in pain clinics)
Study: NCT04822701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 767551 intravenous
Description: BI 767551 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 767551 intravenous
Description: BI 767551 intravenous
Study: NCT05441735

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: APP
Description: APP as an instructional tool for visiting health education
Study: NCT04822701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 767551 intravenous
Description: BI 767551 intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 767551 inhaled
Description: BI 767551 inhaled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravenous
Description: Placebo intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo intravenous
Description: Placebo intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intravenous
Description: Placebo intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhaled
Description: Placebo inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhaled
Description: Placebo inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhaled
Description: Placebo inhaled
Study: NCT06413199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyper Training
Description: Experimental group will perform 2 training session per week for 2 months, 1 set of 10 unloaded repetitions in arms as a warm-up, 4 sets with a goal of 8-12 Reps with 90 seconds rest between sets. 1.5 second concentric and 1.5 second eccentric contraction of bench press, The elbows had to be fully locked out to be counted as a repetition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1 Repetition maximum training group
Description: 2 training session per week for 8 weeks, 1 set of 10 unloaded repetitions in arms as a warm-up, 1 Repetition maximum training group consisted of 5 attempts to lift as much weight as possible one time for that training visit with 90 seconds of rest between attempts, the load was progressively increased each attempt to try to reach or exceed their previous 1 repetition maximum.
Study: NCT04654533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COSC
Description: COSC is professional development program for early childcare providers adapted from the Circle of Security-Parenting (COSP) model. It is a manualized intervention that leverages research on attachment relationships combining psycho-education with a mentalization-based approach. The model uses pre-produced video vignettes of secure and problematic caregiver-child interactions to illustrate how caregivers' may struggle in meeting children's' attachment needs.~Participants are invited to reflect on how they meet and perhaps still not meet the needs of the children in their care with a particular focus on the challenging or 'difficult' children.~The COSP manual has been translated into Danish (Cooper, Hoffman and Powel, 2020, translated by Pedersen, Kronendorf von Wowern, Lier, \& Smith-Nielsen), and the additional COSC material has been translated into Danish for the purpose of this study.
Study: NCT05133882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib Besylate
Description: The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib Besylate
Description: The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib Besylate
Description: The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs
Study: NCT04940845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-20090-2
Description: Subcutaneously injection of HS-20090-2 (60mg/1mL) once on the first day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia
Description: Subcutaneously injection of Prolia® (60mg/1mL) once on the first day
Study: NCT06084442

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of The Techniques of Lateral Rectus Muscle Combined Recession with Hang Back and Combined Recession with Z-Tenotomy in Correcting Large-Angle Exotropia
Description: Patients will be divided into 2 groups:~* Group (A): Patients will undergo combined LR recession 7mm and hang back technique.~* Group (B): Patients will undergo combined LR recession 7mm and Z-tenotomy technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of The Techniques of Lateral Rectus Muscle Combined Recession with Hang Back and Combined Recession with Z-Tenotomy in Correcting Large-Angle Exotropia
Description: Patients will be divided into 2 groups:~* Group (A): Patients will undergo combined LR recession 7mm and hang back technique.~* Group (B): Patients will undergo combined LR recession 7mm and Z-tenotomy technique.
Study: NCT04667793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab + Chemotherapy
Description: Toripalimab: 200mg, q3w, i.v., 2-4 cycles~Chemotherapy:~Thymoma: Cisplatin+Amycin+Cyclophosphamide Thymic carcinoma: Carboplatin+Paclitaxel
Study: NCT05703191

Intervention type: DEVICE
Intervention: Nitric Oxide Generator and Delivery System
Description: Initial at 20ppm is recommended by guidelines. The concentration is adjusted based on actual condition of subjects.
Study: NCT05090891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB000928
Description: INCBG000928 will be administered QD orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo will be administered QD orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered QD orally
Study: NCT05864144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-101 (anti-VISTA)
Description: SNS-101 IV every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-101 (anti-VISTA)
Description: SNS-101 IV every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-101 (anti-VISTA)
Description: SNS-101 IV every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab IV every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab IV every 21 days.
Study: NCT06002945

Intervention type: OTHER
Intervention: Blood sample
Description: Each blood draw will involve removing approximately 75 mL (5 tablespoons) of blood
Study: NCT05898126

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renin-guided hemodynamic management
Description: If normalization of renin levels is achieved (values within the normal laboratory range), we will continue with usual care according to local protocols.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Standard of care
Study: NCT05939999

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Elastic tape (ET)
Description: The elastic tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Sham (SH)
Description: The micropore tape will be allocated in the chest wall and abdomen of individuals and will be used during the 8 weeks of rehabilitation protocol.
Study: NCT05094648

Intervention type: OTHER
Intervention: high flow nasal therapy
Description: effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive

Intervention type: OTHER
Intervention: high flow nasal therapy
Description: effect of high flow nasal therapy in covid 19 patients who pass and who need non invasive
Study: NCT06363734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib plus Dalpiciclib
Description: osimertinib 80mg daily plus dalpiciclib 125mg daily for 21 days followed by 7 days off in each 28-day treatment cycle